Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Treprostinil in PH Associated With Sickle Cell Disease
NCT03055234Phase 3Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2017
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension (PH) comparing Oral Treprostinil with Placebo (2 arms). Primary endpoint: Time to first adjudicated PH clinical worsening event up to 4 years. Planned start Jun 2017; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03055234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055234.